Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

A patient’s IGHV mutation status is a key factor in CLL prognosis. Doctors looking for a patient’s IGHV mutation status are looking at the age of the cell that allowed CLL to grow. If it is a younger, ...

Lomond Therapeutics Holdings, Inc. ("Lomond Therapeutics"), a clinical-stage biotechnology company dedicated to discovering and developing potentially best-in-class and first-in-class medicines for ...

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

which identifies the specific abnormalities in the CLL cells, and a mutation test, which can identify the maturity of CLL cells The course of treatment can then be determined, e.g., a ...

Some CLL patients may receive chemotherapy because of a particular gene mutation or some other circumstance that would keep them from being able to take a targeted therapy safely. Standard ...

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts in white blood cells (called lymphocytes) in the bone marrow. CLL mainly affects older adults and accounts for about one-third of all ...

Chronic lymphocytic leukemia (CLL) is a slow-growing cancer that affects white blood cells. Survival rates tend to be high, but these may vary. Leukemia is a type of cancer involving human blood ...

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

During a Case-Based Roundtable® event, John N. Allan, MD, discussed how new regimens using BTK inhibitors and venetoclax ...